Oncimmune Appoints CMO
This article was originally published in Scrip
Executive Summary
Oncimmune, a leader in early cancer detection, has named Dr. James Jett chief medical officer. Jett is currently professor of medicine in the division of oncology at National Jewish Health in the US, where his research includes conducting clinical trials related to the screening and early detection of lung cancer. Prior to joining National Jewish Health in 2010, he held appointments as professor of medicine at Mayo Medical School and the University of Pittsburgh.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.